Urodynamix starts U.S. clinical study of NIRS technology

By Elaine Rigoli

Tampa, Fla., Sept. 26 - Urodynamix Technologies Ltd. said it started the first U.S.-based clinical study to assess the effectiveness of its near-infrared spectroscopy urodynamics device for measuring bladder function in male subjects with obstruction or lower urinary tract symptoms, caused by prostate disease and benign prostatic hyperplasia.

The Vancouver, B.C., biotechnology company said the study will determine whether URO-NIRS technology is as effective as conventional invasive urodynamics evaluation in male subjects who experience lower urinary tract symptoms.

Urodynamix said it expects to enroll 24 patients in the clinical study over the next eight weeks.

"We hope to improve the quality of care for these patients by providing a comfortable, non-invasive alternative to conventional catheter-based urodynamics testing," president and chief executive officer Barry Allen said in a news release.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.